A B S T R A C T Radioiodinated Factor IX was cleaved by a crude sonicate from leukocytes. In the absence of calcium, fragments of <15,000 mol wt were seen from reduced samples on gel electrophoresis. After digestion in 2 mM calcium, however, electrophoresis of reduced samples showed, in addition to low molecular weight fragments, protein bands corresponding in size to heavy and light chains of Factor XIa-activated Factor IX. The cleaving activity in leukocyte sonicates was inhibited by soybean trypsin inhibitor, but only to a small extent by aprotinin.
INTRODUCTION
It is well established that Factor XIa activates Factor IX by two activation cleavages (1) . However, no plasma cofactor or means of achieving a sufficient local concentration of these trace plasma proteins has been identified. Under some conditions, it has also been shown that Factor VIIa with tissue factor cleaves Factor IX (2) , but the significance of this proteolysis has not been well established. Even less is known about the susceptibility of Factor IX or IXa to degradative cleavages, although partial degradation would serve as a potent means of limiting the coagulation response at an early stage.
In contrast to a system of proteolysis composed of interactions between plasma proteins, physiologic or pathologic cleavage of Factor IX could occur by cellular neutral proteases. This possibility was suggested by data of Kingdon et al. (3) who noted generation of a Factor IXa-like procoagulant activity when a crude concentrate containing Factor IX was incubated with a granulocyte sonicate. The degree of activation, however, could not be assessed by their clotting assays which would have been sensitive to modification of Factor VIII or other effects upon their generated Factor IXa-like activity. Furthermore, their activity re-quired a plasma protein fraction as a cofactor, conceivably to prevent inactivation of Factor IX. Probably the major neutral protease from granulocytes is an elastase. In patients with disseminated intravascular coagulation, high levels of granulocyte elastase were detected in plasma, complexed to a,-antitrypsin (4) . Indeed, this elastase is released during in vitro clotting of whole blood or even recalcified plasma enriched with isolated neutrophils (5) . Elastase would thus be available to cleave clotting factors, at least at local sites of inflammation, before its inactivation.
In approaching the problem of Factor IX proteolysis by granulocytic enzymes, we initially found that crude granulocyte preparations would cleave '25I-Factor IX to yield either low molecular weight peptides or, in the presence of calcium, heavy chain and light chainsized fragments, suggestive of activation.' As an extension of this preliminary observation, we have now examined the effect of granulocyte elastase on Factor IX in an isolated system. Electrophoresis of reduced '25I-Factor IX samples was used as an index of cleavage. Because there has been no specific functional assay for Factor IXa, an immunospecific, radiolabeled-inhibitor assay was developed to test for generation of the Factor IX active site.
METHODS
Materials. Chemicals were purchased from the following sources: Coomassie Brilliant Blue (R-250), Methyl Green, acrylamide, N,N'methylenebisacrylamide, N,N,N'N'-tetramethyl-ethylene diamine, sodium dodecyl sulfate, ammonium persulfate, carboxymethyl (Cm)2 cellulose (Cellex-CM), and lactoperoxidase-glucose oxidase reagent (Enzymobead) from Bio-Rad Laboratories, Richmond, CA; Sepharose 4B and Sephadex G-25 and G-75 from Pharmacia Fine Chemicals, Piscataway, NJ; Ficoll (Histopaque-1077), dextran (industrial grade, 161,000 average mol wt), trypsin inhibitor (type I-S from soybean), Na-p-toluenesulfonyl (Tos)-L-Lys chloromethyl ketone, L-1-tosylamide-2-phenyl-ethyl chloromethyl ketone, NaCl. From the final centrifuged precipitate, the granulocytes were resuspended in 20 ml 0.34 M sucrose with 10,000 U heparin and lysed by aspiration and expression 18 times through a 20-gauge needle. Cellular debris was removed by centrifugation at 1,000 g for 10 min. The granule fraction was obtained as a pellet from a second centrifugation at 28,000 g for 30 min; the pellets were resuspended in 4 ml Tris-buffered saline and stored at -80°C. Three preparations from 4 U of granulocyte-rich fraction were combined and sonicated in a Bransonic-12 water bath for 3 min and then centrifuged at 40,000 g for 30 min. The pellets were resuspended in 30 ml Tris-buffered saline and frozen and thawed five times to ensure granule membrane lysis. Granule supernatants obtained subsequent to freezing, thawing, and centrifugation (40,000 g for 30 min) were combined and dialyzed against Tris-buffered saline.
Isolation of elastase isozymes. Affinity and ion-exchange chromatography were performed similarly to the method of Baugh and Travis (12) , except soybean trypsin inhibitor was used as the affinity ligand instead of aprotinin. Soybean trypsin inhibitor-agarose was prepared by CNBr activation (6) of 50 ml Sepharose 4B, followed by stirring overnight with 1 g soybean trypsin inhibitor at 4°C. Columns (2.5 X 4 cm) of resin were equilibrated with Tris-buffered saline and the sample of lysed granules from 12 U of buffy coat applied. The column was consecutively washed with 100 ml each of Tris-buffered saline and 0.5 M NaCl in 50 mM Tris (pH 7.5).
Crude elastase was eluted with 50 ml 0.1 M acetic acid. After dialysis against 0.15 M NaCl in 10 mM sodium acetate (pH 5.6), the crude preparation was applied to a Cm-cellulose column (1 X 20 cm) equilibrated with the same buffer. After a 150-ml wash with start buffer (to an A280 below 0.01), a 3 Purified by Dr. Kisiel as described for alloantibodies (10) The mixture was desalted on a 10-ml column of Sephadex G-25 (medium) that had been prewashed with 2 ml of 10% bovine albumin in Tris-buffered saline and rinsed with 10 ml of the same buffer without the albumin. The reaction mixture was applied to this column and was then eluted with Tris-buffered saline. For the assay, purified goat anti-Factor IX, which contained 19 mg/ml protein and 800 Bethesda inhibitor U/ml, was diluted 1:500 in 0.1 M NaHCO3 (pH 9.5) and 100 ul was incubated for 1 h at 37°C in microtiter wells (Imulon-I Removawell Strips, Dynatech Laboratories, Inc., Alexandria, VA). After incubation, wells were washed three times with Tris-buffered saline containing 0.1% albumin. Unlabeled Factor IX was incubated with enzymes as indicated above in the cleaving assay; reactions were terminated by diluting an aliquot into an excess of '25I-antithrombin III with heparin. The Factors IX and/or IXa-antithrombin III mixtures were then diluted to 120 Ml with 0.1% albumin in Tris-buffered saline, and 100 Ml transferred to the antibody-coated wells; incubations were 2-6 h at room temperature. After this incubation, wells were washed three times with Trisbuffered saline containing 0.1% albumin and counted. Percentage binding was determined from precounting of the wells before washing. For some assays, EDTA or a1-antitrypsin were added.
Enzyme assays. Elastase activity was determined by the spectrophotometric method of Visser and Blout (16) using N-t-BOC-L-Ala-p-nitrophenyl ester as the substrate; the procedure was performed in phosphate buffer at pH 6.5 and 30°C, using a Gilford spectrophotometer with auto cuvette positioner and recorder (models 252, 2451-A, and 6051, respectively, Gilford Instrument Laboratories, Inc., Oberlin, OH). One unit of activity was arbitrarily defined as the release of 1 ,umol p-nitrophenol min-'ml-' and activity was recorded as AA3475 min-'. Under these conditions, a 1% change in elastase concentration was detectable. The hydrolysis of NBz-L-Tyr ethyl ester was determined by the method of Hummel (17) and, the N-Cbz-L-Lys-p-nitrophenyl ester by the method of Silverstein (18) . Protein concentrations were calculated from A280 with E1% m values of 9.85 and 13.3 for elastase (12) and Factor IX (19) , respectively. For routine inhibitor studies, granulocyte enzyme fractions were incubated with a final concentration of 1 mM L-1-tosylamide-2-phenylethyl chloromethyl ketone, Tos-L-Lys chloromethyl ketone, or MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone at 4°C for 18 h before dilution for esterolytic assays or determination of '25I-Factor IX digesting activity.
Factor IX clotting activity and inhibition were determined by the one-stage partial thromboplastin time with kaolin and deficient plasma as previously described (6) . For Factor IXa coagulant activity, kaolin was omitted and substrate plasma, phospholipid, and sample were warmed for 15 s at 370C before recalcification; tipping in siliconized glass tubes and reagents were as otherwise described for the assay with contact activation (6) . In testing for inhibition of Factor IX coagulant activity, elastase-degraded Factor IX was added to normal and Factor IX-deficient plasmas before the kaolin activated, one-stage assay.
RESULTS
After the separation of leukocytes and hypotonic lysis of erythrocytes, granulocytes represented 96% of the white cells on the basis of differential cell counts. In preliminary experiments, granule extracts were found to digest 125I-Factor IX into peptides and fragments of mol wt <15,000. However, when cleavage was performed in the presence of 2 mM calcium, and the reduced samples electrophoresed, half of the radioactivity appeared in bands of higher molecular weight. These corresponded in size to the heavy and light chains of Factor XIa-activated Factor IX (see Fig. 1 Gel Length (mm) FIGURE Three smaller peaks were demonstrated by absorbance at 280 nm during gradient elution of four separate preparations. All four Cm-cellulose fractions (the breakthrough and three elution peaks, subsequently referred to as fractions I-IV, respectively) contained Factor IX digesting and elastase-like esterase activity. Fraction I was further purified on G-75 Sephadex where elastase and Factor IX cleaving activities were confined to the void volume; lower molecular weight proteins and peptides were inactive in both assays. Fraction IV showed two distinct bands (Fig. 3 ) upon disc-gel electrophoresis at pH 4.3. Nonfixed gels, which had been run at the acidic pH, were sliced and eluted into Trisbuffered saline (0.2 ml for each 1-mm slice); each of the two peaks contained elastase-like esterase (Fig. 3) and '25I-Factor IX-cleaving activities. On gel electrophoresis, fraction I contained a single broad band from 10 to 13 mm migration, fraction II had a doublet of bands at 12 and 13 mm, and fraction III yielded a banding pattern with features of both fractions II and IV (not shown).
The elastase fractions were further characterized by their interactions with chloromethyl ketones. Using the sensitive N-t-BOC-L-Ala-p-nitrophenyl ester assay for elastase activity, 27 and 25% inhibition of the activity of fractions I and II, respectively, were obtained with the chymotrypsin inhibitor, tosyl-amide-2-phenylethyl chloromethyl ketone, whereas the trypsin inhibitor, Na-Tos-L-Lys-chloromethyl ketone, inhibited only fraction I, reducing its activity by 18%. These two inhibitors had no effect upon the esterase activity of fraction IV. However, with MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone, the specific inhibitor of elastase (7) , 73-75% inhibition of the initial esterase activity of all fractions was obtained. These results suggest that Cm-cellulose fractions I and II were contaminated with traces of a chymotrypsin-like enzyme and that fraction I also contained a trypsin-like enzyme. Attempts to isolate the latter by chromatography on lysyl-agarose were unsuccessful. The effects of these inhibitors on cleavage of Factor IX by the elastase fractions are shown in Table I . Inhibition of the esterase of fraction IV by MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone was studied further. Isozymes eluted from gels (see Fig. 3 ), and a separate incubation (1.5 ug elastase in 100 Ml) were >99% inhibited after 2-h incubations at 37°C with a 1 mM final concentration of the specific inhibitor. In comparison, 10 ,ug porcine pancreatic elastase contained 0.98 u. Effects of granulocyte elastase on Factor IX. In a preliminary experiment, it was shown that within 1 min, 1 il normal plasma completely inhibited the N-t-BOC-L-Ala-p-nitrophenyl esterase activity of fraction IV (1 jig in 10 il). To assess the effects of elastase on Factor IX coagulant activity, a purified Factor IX sample was incubated with elastase and aliquots were diluted into Factor IX-deficient plasma, thereby using the plasma protease inhibitors to inactivate the granulocyte enzyme. Clotting activities were then determined and are shown in Fig. 4 . The incubation mixtures contained unlabeled and a trace of '251-labeled Factor IX. In addition to dilution of aliquots into plasma for determination of coagulant activity, aliquots were also taken at 10 min, reduced, and run on 10% polyacrylamide gels in sodium dodecyl sulfate. After slicing, 28% of the label remained in the uncleaved Factor IX position, in good agreement with the 25% remaining coagulant activity at this time. In separate experiments, the proteolysis of '251-Factor IX by fraction IV showed the same calcium-dependent specific cleavages (Fig. 5) as previously found when the crude granulocyte preparation was used. As before, in the absence of calcium, only fragments of <15,000 mol wt were obtained. Fig. 1 legend) . From 70 to 85% of the 3-5,000 cpm applied were recovered and an average of 95% of these were present in the slices indicated; percents in vertical columns were adjusted to 100% of counts present in the indicated peaks. Abbreviations used in this table: E-CMK, MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone; TPCK, L-1-tosylamide-2-phenylethyl chloromethyl ketone; and TLCK, Na-Tos-L-Lys chloromethyl ketone.
Peaks typically migrated within the millimeters of gel specified when the marker dye front migrated 80 mm toward the cathode (total gel lengths were near 100 mm). Fragments, however, varied from representing two distinct peaks to a single, broad zone of radioactivity beyond the light chain peak. FIGURE 4 Inactivation of Factor IX coagulant activity by elastase. Factor IX was incubated with Cm-cellulose fraction IV in 1:5 (0) or 1:10 (L) elastase to Factor IX ratios. At timed intervals, twenty-fold dilutions into Tris-buffered saline were made and the Factor IX clotting activity of a 0.1-ml aliquot determined. Activity was compared with a standard curve determined with normal pooled plasma; the control (0) represents Factor IX without elastase; elastase alone at this dilution had no effect on a partial thromboplastin time of normal plasma (not shown).
To explore whether a Factor IXa species was formed either partially or transiently during cleavage by fraction IV, an immunospecific, labeled-inhibitor assay was used. It had been shown that (a) Factor IX itself would not bind 125I-antithrombin III; (b) during incubation with Factor IXa, a time-dependent increase of binding of the labeled inhibitor was observed; and (c) at its lower limit, the assay could detect as little as 2 ng Factor IXa in volume of 0.1 ml (20, 21) .
In preliminary experiments, elastase incubated with unlabeled Factor IX at an enzyme to substrate ratio of 1:10 Factor IXa was studied to compare effects of elastase on the zymogen and its active enzyme. In studying clotting activity (using Factor IX-deficient plasma for substrate and elastate inhibition and no contact phase activators) 2-id aliquots of Factor IXa decreased the clotting times of the final 302 ,l assay from 67 to 82 s, but clotting remained at that level after both 10-and 20-min incubations. For these studies, elastase to Factor IXa ratios were 1:8.
The effects of elastase on Factor IXa were further studied by examining patterns of reduced samples of FIGURE 5 Cleavage of '25I-Factor IX by elastase. Factor IX (1 ,ug), containing a trace of 125I-Factor IX, was incubated at 37°C for 30 min with Cm-cellulose fraction IV at a 1:10 elastase to Factor IX ratio. Incubation was carried out in Tris-buffered saline, pH 7.75, in the presence (*) or absence (0) of 6 mM calcium chloride. The samples were reduced and electrophoresed and the gels sliced and counted as described for Fig. 1 and in Methods. 42  0  0  0  0  23  0  0  0  0  Intermediate  17  8  3  0  0  16  6  5  0  0   Heavy chain  10  25  24  32  21  17  27  27  26  23  Light chain  18  32  29  6  4  26  29  29  28°20°F  ragments  13  35  44  52  751  18  38  39  46   57t Peak slices (in millimeters), recoveries, and calculations of percent of counts per minute are expressed as described in notes to Table I . For these studies, '"I-Factors IX or IXa were incubated with elastase as described in the Methods. At the times given (10 s-60 min), a 10-fold excess by weight of a1-antitrypsin to elastase was added for 10 min at 37°C to inhibit the granulocyte protease. Samples were reduced with dithiothreitol (13) and electrophoresed on 10% polyacrylamidegels in sodium dodecyl sulfateas described in the text. Parallel, timed incubations (without labeled clotting factor) were taken and incubated with '"I-antithrombin III for the immunospecific Factor IXa assay (see Table  III ).°A lthough distinct peaks were observed within these light chain regions, the radioactivity peak was 4 mm (two slices) more anodal than in the previous cleavages indicating a somewhat smaller size. t At 60-min digestion, fragments included -40 and 30% of total counts that migrated beyond the marker dye for Factors IX and IXa, respectively (i.e., counts between 80 and 90 mm toward the cathode on 100-mm gels).
'25I-Factor IXa on gels as shown in the right portion of Table II . For these particular preparations of Factor IX, '25I-Factor IX and Factor XIa, approximately onefourth of the 1251-Factor IX remained uncleaved after 1-h incubation with Factor XIa, the latter at a 1:60 enzyme to substrate ratio. The time-dependent increase of low molecular weight fragments (<15,000 mol wt, Results are expressed as counts per minute bound (over background) and, in parentheses, percent, of the counts bound (vs. precounted wells). Controls with Factor IX before elastase incubation or with albumin instead of the clotting factor ranged from 0.7 to 0.9% 125I-antithrombin III bound. After Factor XIa activation, again without elastase, Factor IXa gave 8.5% binding on simultaneous controls with the same preparation of labeled inhibitor. An average of 9,550 cpm were added and duplicate determinations (n = 10 pairs) varied by an average of 5% for Factor IXa, and for Factor IX, 9% of the counts per minute bound.
These experiments were set up in parallel with those in Table  II , although the trace label with "ssI-Factor IX was omitted and (after the 10-min incubation with a1-antitrypsin) samples were incubated with lssI-antithrombin for 10 min and then for 2 h at 23°C in anti-Factor IX-coated wells as described in the text.
or those migrating further than the light chain) were quite similar to results with '251-Factor IX, including the presence of radioactivity migrating beyond the marker dye after 1 h of digestion with elastase. As with Factor IX, parallel experiments in which '25I-Factor IX was omitted were run for Factor IXa to assess antithrombin III binding. As shown in Table III , there was a gradual decline of the ability to bind antithrombin III that corresponded, at least roughly, to the decrease in Factor IXa clotting activity in separate experiments described above.
Possible inhibitory effects of elastase-degraded Factor IX upon Factor IX procoagulant activity were screened as follows. Factor IX was digested by elastase (as in the left-hand portion of Table II) for 60 min and dilutions were added to plasmas at levels of 1/10 (50 ng/ ml), equal to (500 ng/ml), and in 10-fold excess of (5 ,ug/ml) the concentration of Factor IX in the initial (29) . The enzyme-inhibitor complex also distinguished the activated form from inactive, degraded products of Factor IX. A similar approach has been used to differentiate between inactivation and activation when Factor IX is digested with chymotrypsin and trypsin (20) . It has also been used to demonstrate that a mouse monoclonal antibody that reacts to the heavy chain of Factor IXa does not inhibit either Factor XIa activation cleavages and/or subsequent binding of antithrombin III-heparin (21) . By detecting generated active sites of Factor IX, the direct assay eliminates the possibility of interference due to effects on Factor VIII as would occur in coagulation or coupled Factor X activation assays.
Elastase can degrade antithrombin III (30) , and this effect appears to be operative in the new Factor IXa assay. Therefore, the elastase-specific chloromethyl ketone or al-antitrypsin were used to control for this effect. Even with such control and throughout the time course experiments, elastase-degraded Factor IX was unable to bind antithrombin III. In separate experiments, the procoagulant activity of the Factor IX zymogen was rapidly destroyed. This occurred despite the rapid digestion of Factor IX to form heavy and light chain-sized fragments and only a slower digestion to lower molecular weight fragments (providing calcium was present). Since similarly sized peptide fragments result from elastase and Factor XIa digestions, it appears that elastase hydrolyzes peptide bonds near, but not at, the specific Arg145-Ala146 and Arg180-Val181 bonds known to be necessary for activation of Factor IX (31) . Indeed, similar to the case with thrombin (32), it is probable that the free amino group of Val18g, at the amino terminus of the Factor IXa's heavy chain, is necessary for ion pair formation with ASp365 to create a functional active site.
The interaction of elastase with Factor IXa produced the same, relatively slower, digestion to lower molecular weight fragments as with the zymogen (see Table II ). On the other hand, Factor IXa was only partially inactivated by elastase as indicated by both '251-antithrombin III-heparin binding and coagulant activity in a nonactivated assay with Factor IX-deficient plasma. The difference of the current results with Factor IXa and those previously reported using crude preparations (27) are best explained by other effects of elastase on the coagulation system. Indeed, when elastase was not inhibited following even brief incubations with Factor IXa, no binding of '251-antithrombin III was detected. As mentioned previously, this was apparently because of degradative effects of the elastase on antithrombin III. Thus, it appears that Factor IXa is more resistant to inactivation cleavages than is the zymogen. In this regard, studies in which elastase-degraded Factor IX were incubated with Factor XIa are of interest. Although screening for generation of coagulant activity was negative, some '251-antithrombin binding was observed after short incubations. This presumably relates to the degree of preservation of an active site capable of interacting with either lower molecular weight substrates or less specific inhibitors (including antithrombin III) but sufficient cleavage to destroy secondary binding sites that are needed for physiologic, macromolecular substrates. An analogous situation would be lack of fibrinogen clotting by y-thrombin despite retention of the ability to bind antithrombin III (33) .
The assay using antithrombin III binding to distinguish an active coagulation factor from its zymogen is readily applicable to other coagulation proteins. A similar approach has recently been reported for Factor X (34) . Adaptations of these types of assays to more complex conditions, for example, to detect Factor IX activation in plasma, whole blood, or even in vivo, should provide insights into the early steps of coagulation in normal and abnormal hemostasis.
